Pharma and Healthcare market data, analysis and forecasts from Business Monitor International, the trusted source for business information and industry intelligence across global markets.
Pharma and Healthcare Insight provides market intelligence, trend analysis, forecasts and ratings for the global Pharma and Healthcare industry on a country-by-country basis across the Americas, Emerging Europe, Western Europe, Asia, and the Middle East & Africa. Combined with competitive intelligence on the growth strategies of the leading national and multinational companies, Pharma and Healthcare Insight allows you track key developments across the global Pharma and Healthcare industry.
Subscribers receive password access to the latest intelligence, a searchable 24-month archive of Pharma and Healthcare Insight articles and data plus the ability to download PDFs of current and back issues.
›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.
›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.
To access our feed of headlines copy this link to your RSS reader
Follow Pharma and Healthcare Insight on Twitter
Industry
BMI View: Multinational drug companies are negotiating the negative effects of the patent cliff with better than expected strategies and tactics. This has impressed investors and shareholder value for many of the large firms has increased over the past couple of years, in some cases above the wider equity markets. Numerous challenges are on the short-term horizon, primarily the...
2012-05-15Industry / Brazil
BMI View: The Brazilian government's good pharmaceutical practice programme will moderately improve the efficiency of the country's public pharmaceutical distribution system. However,...
2012-05-04Industry / United States
BMI View: Despite reports to the contrary in March 2012, Pfizer appears committed to retaining its generic drugs and branded off-patent medicine business. This is understandable as...
2012-05-04Industry / India
BMI View: Cipla's decision to cut the prices of three of its cancer drugs could significantly benefit patients in India and other developing countries, especially in Africa, who previously could not afford them. However, for many people these medicines are still unaffordable and the supporting healthcare infrastructure, such as hospitals and doctors and nurses, are often not accessible...
2012-05-08Industry / India
BMI View: India's growing reputation as a pharmaceutical manufacturing hub is somewhat overhyped. The country exports medicines to developed states and emerging markets but these products...
2012-03-30Industry / Germany
BMI View: India's issuance of a compulsory licence for a patented drug is highly significant for several key stakeholders. Patients will now have increased access to a medicine that...
2012-03-15Industry / Turkey
BMI View: Of the companies we expected to purchase Mustafa Nevzat Ilac Sanayi (MN Pharmaceuticals), Amgen was the bottom of our list. In terms of synergies and similarities between the two companies, they are as different as is possible. However, this transaction makes a lot more sense when considering Amgen's slow and strategic shift from being a leading global biotech company...
2012-04-26Industry / Bulgaria
BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)...
2012-04-05Industry / Poland
BMI View: The European Court of Justice (ECJ)'s ruling on the illegality of a provision of Poland's 2001 law on medicinal products, which had allowed the sale of cheap medicine imports...
2012-04-02Industry / Qatar
BMI View: Unlike other countries in the Middle East that have focused on encouraging pharmaceutical companies to establish manufacturing facilities, Qatar's focus is on education and research. As the country lacks the freight and shipping infrastructure of the UAE it makes sense that it is not trying to compete in this area.
2012-05-11Industry / Israel
BMI View: While Teva's Q112 results were not terrible compared to Q411, as revenues and profits both saw reasonable growth, and considering the recent acquisitions of Cephalon and Taiyo,...
2012-05-10Industry / Algeria
BMI View: It is in the interest of local and multinational drugmakers to assist African markets in the field of pharmacovigilance (PV). Unfortunately, while PV systems are important...
2012-05-09Industry / Switzerland
BMI Core View: The uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which is increasingly important as developed states reform their healthcare systems over the medium term. Key obstacles include prescribers' brand loyalty, pay-to-delay deals, the near-universal unpopularity...
2012-05-08Industry / United Kingdom
BMI View: The continued global generic competition to Nexium (esomeprazole) and Seroquel (quetiapine) will test AstraZeneca's strength in 2012. We believe this, in addition to government...
2012-05-02Industry / United Kingdom
BMI View: GlaxoSmithKline (GSK)'s Q112 results highlight the company's high exposure to healthcare sector cost-containment programmes and the pricing pressure placed on medicines by...
2012-04-27
